The latest on Moderna, Apellis, and Merck

Need to keep on high of the science and politics driving biotech in the present day? Enroll to get our biotech e-newsletter in your inbox.

Howdy, everybody. Damian right here with the fallout from Pfizer’s downbeat replace, a brand new entrant in weight problems analysis, and an orthogonal CRISPR enterprise.

The necessity-to-know this morning

• Apellis Prescription drugs stated a European advisory committee is predicted to recommend against the approval of Syfovre, its eye drug for a typical type of blindness. The corporate plans to enchantment the adverse ruling.
• Sage Therapeutics and Biogen introduced the commercial launch of Zurzuvae, an oral therapy for ladies with postpartum despair.
• Merck and Moderna reported three-year follow-up data on their mRNA-based immunotherapy for superior melanoma. Part 3 research are underway.
• The FDA accepted Amgen’s marketing application for tarlatamab, a bispecific antibody to deal with superior small cell lung most cancers. The approval determination date is June 12, 2024.

Is it time to fret about Moderna?

Yesterday’s information that Pfizer is anticipating to promote far fewer Covid-19 vaccines than Wall Avenue anticipated despatched shares of Moderna down as a lot as 6% on fears that the corporate might be in for a painful revision of its personal.